Candel Therapeutics (CADL) shares rose nearly 3% in recent trading Tuesday after the company reported its Q2 results.
Candel booked a diluted net loss of $0.74 per share, widening from a loss of $0.33 a year earlier.
No comparable estimates were available on Capital IQ.
As expected, no revenue for the quarter ended June 30 was reported.
The company said it had $21.5 million in cash and cash equivalents, and expected it to fund operations through Q1 2025.
Price: 5.74, Change: +0.16, Percent Change: +2.87
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments